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Abstract
Background: Genetic factors influencing the prognosis of gastric adenocarcinoma (GAC) are not well known. Given the
relevance of cytokines and other pro-inflammatory mediators in cancer progression and invasiveness, we aimed to assess
the prognostic role of several functional cytokine and cyclooxygenase gene polymorphisms in patients with GAC.
Methodology: Genomic DNA from 380 Spanish Caucasian patients with primary GAC was genotyped for 23 polymorphisms
in pro-inflammatory (IL1B, TNFA, LTA, IL6, IL12p40), anti-inflammatory (IL4, IL1RN, IL10, TGFB1) cytokine, and cyclooxygenase
(PTGS1 and PTGS2) genes by PCR, RFLP and TaqMan assays. Clinical and histological information was collected prospectively.
Survival curves were estimated by the Kaplan-Meier method and compared using the log rank test. Outcome was
determined by analysis of Cox proportional hazards, adjusting for confounding factors.
Results: The median follow-up period and median overall survival (OS) time were 9.9 months (range 0.4–120.3) and 10.9
months (95% CI: 8.9–14.1), respectively. Multivariate analysis identified tumor stages III (HR, 3.23; 95% CI:2–5.22) and IV (HR,
5.5; 95% CI: 3.51–8.63) as independent factors associated with a significantly reduced OS, whereas surgical treatment (HR:
0.44; 95%CI: 0.3–0.6) was related to a better prognosis of the disease. Concerning genetic factors, none of the 23
polymorphisms evaluated in the current study did influence survival. Moreover, no gene-environment interactions on GAC
prognosis were observed.
Conclusions: Our results show that, in our population, the panel of selected pro- and anti-inflammatory cytokine, and
cyclooxygenase gene polymorphisms are not relevant in determining the prognosis of gastric adenocarcinoma.
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Introduction
Gastric adenocarcinoma (GAC) still remains the second leading
cause of cancer death worldwide. Despite advances in treatment,
overall 5-year survival is less than 40% in Western countries [1,2].
Poor prognosis of patients with GAC has been associated with
several conditions such as tumor-node-metastasis (TNM) stage [3],
signet-ring cell histology [4], incomplete tumor resection [5], and
high lymph node ratio [6]. Helicobacter pylori (H. pylori) infection and
tobacco smoking, two well establish risk factors for gastric
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carcinogenesis [7–9] have been also evaluated as prognostic
markers for GAC [10–13]. However, few studies have addressed
the relevance of patient’s genetic background on the prognosis of
the disease. Recently, it has been suggested the correlation
between persistence of chronic inflammation and reduced survival
in GAC patients [14,15]. The immune response at the gastroin-
testinal mucosa is regulated by a wide variety of pro- and anti-
inflammatory mediators such as cytokines and growth factors.
Among them, interleukin-1b (IL-1b), tumor necrosis factor-a
(TNF-a), lymphotoxin-a (LT-a), interleukin-6 (IL-6), and inter-
leukin-12 (IL-12) are potent pro-inflammatory cytokines with a
relevant role in both cancer development and progression.
Significant high serum levels of IL-1b, TNF-a, and IL-6 have
been reported in patients with metastatic GAC [16,17]. Moreover,
upregulation of IL-1b and TNF-a seems to be involved in the
molecular mechanisms of the anorexia-cachexia syndrom [18]. By
contrast, IL-12 production by PBMCs (peripheral blood mono-
nuclear cells) after stimulation in vitro with tumor cells or LPS
(lipopolysaccharide) has been found to be significantly depressed in
patients with GAC, specially in the advanced stages of the disease
[19].
On the other hand, IL-4, IL-10, and TGF-b1 are potent
negative regulators of the Th1-type immune response. Studies
carried out in human gastric cancer cell lines found that IL-4
inhibits gastric cell proliferation by blocking cell cycle progres-
sion and down-regulating several key G0–G1 cell cycle nuclear
factors [20]. IL-10 inhibits macrophage activation, cytokine
production, and antigen-specific T-cell proliferation [21].
However, several studies have postulated the involvement of
IL-10 in the onset and spread of GAC [22]. Like IL-10,
enhanced expression of TGF-b1 has been associated with
progression and invasiveness of the GAC [23,24]. Thus,
blockade of TGF-b or TGF-b signaling pathways has been
suggested as potential therapy to prevent GAC cells from
invading and metastasizing [25].
Besides cytokines and growth factors, cyclooxygenases 1
(COX-1) and 2 (COX-2) have been implicated in carcinogenesis
and metastatic progression of many types of cancers including
GAC [26,27]. Cyclooxigenases or prostaglandin G/H synthases
(PTGSs) catalyze the formation of prostaglandins from arachi-
donic acid [28]. COX-1 (PTGS-1) is constitutively expressed
and plays a key role in the protection of gastric mucosa. The
COX-2 isoform (PTGS-2) is induced in response to cytokines,
and other inflammatory and mitogenic stimuli. Whereas the
mechanisms by which COX-1 promotes gastric carcinogenesis
are not well known, up-regulation of COX-2 has been
associated with GAC development and progression by increas-
ing cell proliferation, inhibiting apoptosis, inducing angiogenesis,
and suppressing host immune response [29].
Genes encoding the proteins mentioned above harbor
polymorphic sites that have been reported to influence
transcriptional efficiency and protein levels. At present, there
is very little information concerning the influence of immune-
related gene variants on the prognosis and clinical outcome of
GAC [14,30–32]. Trying to address this specific issue, we aimed
to assess the prognostic role of some functional polymorphisms
in pro- (IL1B, TNFA, LTA, IL6, IL12p40), and anti-inflamma-
tory (IL1RN, IL4, IL10, TGFB1) cytokine as well as in the
PTGS1 and PTGS2 genes in a large prospective cohort of
Spanish Caucasian patients with primary GAC.
Patients and Methods
Study Subjects and Data Collection
Consecutive patients diagnosed with primary GAC from May
2002 to December 2003 in 15 general Spanish hospitals were
invited to take part in the study. Gastric tumors were grouped
according to their anatomical location as cardia GAC (located at
the gastroesophageal junction) [33] and non-cardia CGA.
Moreover, non-cardia GACs were classified according to the
histological type as intestinal, diffuse, or indeterminate [34].
Patients with local recurrence of GAC, non-adenocarcinoma
histology, absence of blood samples, or refusal to participate in the
study were considered non-eligible. Of the 466 patients with GAC
who initially agreed to participate, 400 (85.1%) could be
interviewed, had a complete pathology report, and provided
biological samples of adequate quality for genetic analysis.
However, 20 patients (5%) were excluded from the study due to
lack of follow-up. Finally, 380 GAC patients had adequate
information to estimate follow-up data and survival analysis. The
characteristics of excluded patients did not differ from those of the
final group.
At the time of inclusion, detailed information was recorded
concerning age, gender, smoking habits, family history of GAC,
date of diagnosis, surgical treatment, TNM staging (UICC/AJCC
classification), presence of metastases, tumor location, and
histological subtype. In addition, approximately 10 ml of periph-
eral blood from each patient were collected into ethylenediamine-
tetraacetic acid (EDTA) and serum separator tubes for subsequent
DNA extraction and H. pylori serology, respectively. Once
processed, whole blood and serum samples were aliquoted and
stored at –80uC until analysis. All patients gave written informed
consent to the study, which was reviewed and approved by the
institutional ethics committee of each participating hospital.
Patient’s Follow-up
Each participant hospital performed the follow-up periodically.
Follow-up included computerized tomography of the chest and
abdomen, and hematological analysis at 3-month intervals during
the first year and thereafter at 6-month intervals. Moreover, an
upper digestive endoscopy was performed every year. Information
was updated by clinical specialists through in-person interview,
medical chart review, and in some cases direct calling. The latest
follow-up data in this study were obtained in November 2011.
Diagnosis of Helicobacter pylori Infection
H. pylori status was assessed by both urease test (CLO-test; Delta
West Ltd., Canning Vale, Bentley, Australia) and histological
examination from biopsies taken at the antrum and corpus of the
stomach during the endoscopic procedure. The presence of
antibodies to CagA and VacA antigens was determined in serum
by Western blot analysis (Bioblot Helicobacter; Izasa, Barcelona,
Spain), as previously validated in our area [35]. Patients were
considered positive for bacterial infection if any of the three tests
was positive.
Genetic Polymorphisms
Genomic DNA was extracted from EDTA-preserved whole
blood using the QIAamp DNA Blood Mini extraction kit (Qiagen,
Izasa, Barcelona, Spain). We assessed 22 SNP’s (single nucleotide
polymorphisms) in the IL1B, TNFA, LTA, IL12p40, IL4, IL6, IL10,
TGFB1, PTGS1, and PTGS2 genes, as well as the VNTR (variable
number of tandem repeat) polymorphism in intron 2 of the IL1RN
gene. The panel of polymorphisms was selected a priori based on
three criteria: (a) having a reported prevalence of at least 5% for
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the less frequent allele among Caucasians; (b) having potential
functional consequences leading to altered protein concentrations
or protein function; or (c) published evidence of their involvement
in GAC development, progression and invasiveness. The regions
containing the polymorphic sites were blindly genotyped by RFLP
(restriction fragment length polymorphism)-PCR-based methods
and TaqManH-MGB allelic discrimination assays. Quality control
for the genotyping was achieved by including a negative PCR
control sample (HPLC water) and three positive controls for each
SNP analyzed (homozygous for allele 1, heterozygous, and
homozygous for allele 2). In addition, 10% of the samples were
run twice in separate assays with a genotype concordance of 100%
for all the polymorphisms.
Cytokine gene analysis. Thirteen SNP’s in the IL1B
(2511C.T, rs16944 and +3954C.T, rs1143634), TNFA
(2308G.A, rs1800629 and 2238G.A, rs361525), LTA
(+252G.A, rs909253 and +365G.C, rs746868), IL12p40
(+1180A.C, rs3212227), IL4 (2590C.T, rs2243250), IL6
(+174C.G, rs1800795), IL10 (21087G.A, rs1800896 and
2597C.A, rs2243250), and TGFB1 (+869T.C, rs1800470 and
+915G.C, rs1800471) genes, as well as the VNTR polymorphism
in intron 2 of the IL-1RN gene were analysed by PCR-RFLP-
based methods and TaqManH-MGB assays (Applied Biosystems,
Madrid, Spain) as previously described [36].
PTGS1 genotyping. Subjects were genotyped for three SNPs
in the PTGS1 gene. The PTGS1-1676A.G (rs1330344) and
+644C.A (rs5788) polymorphisms were analyzed using Taq-
ManH-MGB pre-designed assays according to the manufacturer’s
instructions. The fragment containing the PTGS1+50C.T
(Pro17Leu) (rs3842787) polymorphic site was amplified as
described by Gonzalez-Conejero et al. [37]. PCR products were
digested with 2 units of Fau I (New England Biolabs, Izasa,
Barcelona, Spain) for 5 hours at 55uC and electrophoresed on 2%
agarose gels. Digests resulted in an intact fragment of 244 bp
(allele T) or in two fragments of 125 and 119 bp (allele C).
PTGS2 genotyping. Six SNPs located within the PTGS2
gene were studied. TaqManH Pre-Designed Assays were used for
the detection of the PTGS2 -1195G.A, (rs689466), +3050
(V102V)G.C, (rs5277), +8473T.C, (rs5275) and +10335G.A,
(rs689469) polymorphisms. Genotypes for the PTGS2-765G.C
(rs20417) and +9850A.G (rs4648298) polymorphisms were
determined by PCR-RFLP based methods using primers and
reaction profiles as described by Cipollone et al. [38] and Cox et al.
[39], respectively. For typing the rs20417 polymorphism, PCR
products were digested with 2 units of Fau I (New England Biolabs,
Izasa, Barcelona, Spain) for 5 hours at 55uC; digests resulted in
two fragments of 122 and 187 bp (allele C) or in an intact
fragment of 309 bp (allele G). For typing the rs4648298
polymorphism, PCR products were digested with 2 U of Alu I
(Invitrogen, Prat de Llobregat, Barcelona, Spain) for 5 h at 37uC.
This procedure resulted in 349-bp and 196-bp fragments (allele G)
or in the undigested 545-bp fragment (allele A).
Statistical Analysis
Continuous variables were expressed as mean with standard
deviation whereas qualitative variables were expressed as frequen-
cies and percentages. The relationship between qualitative
variables was analyzed by contingency tables with chi-square test
(x2). Overall survival (OS) time was calculated from the date of the
diagnosis to the date of last contact or death from any cause.
Patients who where still alive at the last contact and patients lost to
follow-up were consider as a censored event in the analysis. In
addition, patients’ comorbidity at diagnosis was assessed using a
previously validated adaptation of the Charlson Comorbidity
Index [40]. Concerning gene polymorphisms, estimated haplotype
frequencies and linkage disequilibrium (LD) coefficients (Dand r2)
for the TGFB1, TNFA, LTA, IL10, IL1, PTGS1, and PTGS2 loci
were calculated using the Estimating Haplotype frequencies (EH)
software program (available from http://linkage.rockefeller.edu/
ott/eh.htm. For each marker, the more common homozygous
genotype or haplotype was used as the reference category. Co-
dominant and dominant inheritance genetic models were used for
analysis. Survival among different genotype groups was estimated
using the Kaplan-Meier method and compared using the log rank
test. Univariate and multivariate Cox proportional hazards models
adjusting for age, gender, H. pylori status, smoking habits, tumor
location, histological type, tumor stage, treatment, and Charlson
index, were performed to evaluate the prognostic value of each
polymorphism on patient’s survival. Starting with age and sex,
models were constructed using a step-wise forward unconditional
Table 1. Demographic and clinicopathological characteristics
of patients with GAC (n = 380).
Variable Cathegory
TOTAL patients N
(%)
Gender Male 257 (67.6)
Female 123 (32.4)
Mean age 6 SD (yr) 71.2612
Charlson index ,3 at diagnosis 333 (87.6)
$3 at diagnosis 47 (12.4)
Neoplasia location Proximal 63 (16.6)
Distal 317 (83.4)
H. pylori infection* Positive 245/344 (71.2)
Negative 99/344 (28.8)
CagA toxine Positive 220/344 (64.0)
Negative 124/344 (36)
VacA Positive 145/344 (42.2)
Negative 199/344 (57.8)
Smoking habit Never 176 (46.3)
Current 61 (16.1)
Former 116 (30.5)
Undetermined 27 (7.1)
TNM stage** Stage I 55 (14.5)
Stage II 44 (11.6)
Stage III 66 (17.4)
Stage IV 183 (48.2)
Could not be assesed 32 (8.4)
Curative gastrectomy 170 (44.7)
Chemotherapy 120 (31.6)
Radiotherapy 43 (11.3)
Exitus causes 311 (81.8)
Neoplasia progression 227 (73)
Chemotherapy 3 (0.9)
Surgery 30 (9.6)
Other causes 51 (16.5)
*Information was available for 344 patients.
**Clinical tumor stages according to the International Union Against Cancer
(UICC) criteria.
N = number of individuals.
doi:10.1371/journal.pone.0046179.t001
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method. A variable was entered in the model if the significance
level of its coefficient was less than 0.05 and was removed if it was
greater than 0.10. Potential interactions between genotypes and
clinical and demographic variables were assessed by the
corresponding Cox regression models containing the interaction
term. For all tests, a two-sided p-value ,0.05 was considered
statistically significant. To address the issue of conducting multiple
tests within each polymorphism, an additional Bonferroni
correction was applied (P-value ,0.05/46 = P-value ,0.001).
The statistical analyses were performed using the SPSS software v
15.0 for Windows (SPSS Ibe´rica, Madrid, Spain).
Results
Survival Analysis and Characteristics of GAC Patients
Demographic, clinical, and tumor-related characteristics of
patients included in the study are summarized in Table 1. There
were 257 males (67.6%) and 123 females (32.4%, male/female
ratio 2/1) whose ages ranged from 30 to 96 years. According to
Charlson’s index, most of patients (87.6%) had a low morbidity
index (,3) at the moment of diagnosis. In 63 cases (16.6%),
tumors were located at the cardia, and in 317 cases (83.4%), at the
distal region of the estomach. Among distal GACs, 161 (50.8%)
were of intestinal histotype, 119 (37.5%) of diffuse histotype, and
37 (11.7%) of mixed or undetermined type.
The median follow-up time and the median OS for all patients
in our study was 9.9 months (range: 0.4–120.3) and 10.9 months
(CI 95%: 8.9–14.1) respectively. The mean and median follow-up
for censored patients were 67642 and 73.4 months (range: 0.6–
116.1), respectively. Three hundred and eleven GAC patients
(81.8%) had died at the end of the follow-up period, and in 227
cases (73%) death was related to tumor progression. Figure 1
shows Kaplan-Meier survival curves among GAC patients
regarding clinicopathological features. In the univariate analysis,
male gender, previous or current smoking, proximal location of
the tumor, and advanced tumor stages (III and IV) were associated
with significantly reduced OS, whereas surgical treatment and a
low morbidity index (,3) at the moment of diagnosis were related
to a better prognosis of the disease (Table 2). By contrast, other
clinicopathological features evaluated in our study such as age,
tumor histological type, H. pylori status, or treatment with D1 or
D2 lymphadenectomy did not influence survival.
Survival Analysis and Gene Polymorphisms
Tables 3 and 4 show the survival hazards ratios among GAC
patients according to gene polymorphisms. In the univariate
analysis, no significant differences were found when GAC patients
were analyzed by genotypes for any of the polymorphisms studied.
Only some borderline associations between the TNFA rs1800629
(p= 0.07 for the AA genotype), LTA rs909253 (p= 0.06 for the AG
genotype), IL10 rs2243250 (p= 0.04 for the CA genotype), and
PTGS2 rs4648298 (p= 0.06 for the AG genotype) and OS was
observed. Because there were few GAC patients homozygous for
the minor alleles of the different polymorphisms, the heterozygous
and minor variant homozygous genotypes were combined for
additional analysis, assuming a dominant genetic model. Again, no
association between OS and any polymorphisms was observed.
Further stratification of patients (Tables S1, S2, and S3 and
Figures S1, S2, S3, and S4) by tumor location (cardia vs. non-
cardia) and histological subtype (intestinal vs. diffuse) showed no
differences in OS among the different gene variants evaluated in
the study (Table S4).
An additional haplotype analysis was conducted to evaluate the
combined effect of alleles of different polymorphisms on gastric
cancer survival. As expected, the IL1, TNFA, LTA, TGFB1, IL10,
PTGS1, and PTGS2 loci were in strong linkage disequilibrium (LD)
in our data set (data not shown). Specific LD values for each pair
of loci of IL1, TNFA, LTA, TGFB1, and IL10 genes were similar to
those reported previously [36]. PTGS1 and PTGS2 polymorphisms
were also in strong LD with D’ values higher than 0.75 with the
exception of the PTGS1-1676/PTGS1 644 loci (D’ = 0.21). Table 5
shows the OS analysis according to the most frequent cytokine and
PTGS haplotypes. As with the independent analysis for each
polymorphism, none of the estimated haplotypes showed a
significant association with OS.
Despite the lack of influence of polymorphisms on patient’s
survival, we wanted to examine the potential interaction between
genotypes and the prognostic factors of GAC identified in our
study population (namely TNM stage and surgical treatment).
Figure 1. Kaplan-Meier survival plots presented by (A) TNM stage, (B) surgical treatment, (C) age, (D) gender, (E) smoking habit, (F)
H. pylori infection, (G) tumor location, and (H) histological subtype. Statistical analysis was performed by the log rank test.
doi:10.1371/journal.pone.0046179.g001
Table 2. Overall survival analysis according to
clinicopathological features.
Variable Cathegory N HR* 95% CI P-value
Gender Female 123 – –
Male 257 1.31 1.03–1.68 0.031
Age ,50 years 28 –
$50 years 352 1.08 0.72–1.65 0.70
Charlson index ,3 at diagnosis 333 – –
$3 at diagnosis 47 1.56 1.13–2.17 0.01
Neoplasia location Non-cardia 317 – –
Cardia 63 1.45 1.09–1.96 0.01
Lauren’s classification Intestinal 161 – –
Diffuse 119 1.07 0.82–1.39 0.63
H. pylori infection Negative 99 – –
Positive 245 1.02 0.78–1.32 0.89
CagA toxine Negative 124 –
Positive 220 1.07 0.85–1.37 0.57
VacA Negative 199 – –
Positive 145 0.95 0.75–1.20 0.67
Smoking habit Never 176 – –
Current and former 177 1.27 1.01–1.61 0.04
TNM stage Stage I 55 – –
Stage II 44 1.45 0.85–2.46 0.17
Stage III 66 2.74 1.72–4.36 ,0.001
Stage IV 183 6.30 4.15–9.58 ,0.001
Surgical treatment Yes 247 – –
No 133 3.44 2.68–4.41 ,0.001
Lymphadenectomy D1 57 – –
D2 73 1.13 0.74–1.71 0.58
*Univariate analysis showing unadjusted Hazard Ratio (HR) values.
N = number of individuals.
doi:10.1371/journal.pone.0046179.t002
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Smoking habit, and H. pylori infection, two well known risk factors
of GCA were also included for gene-interaction analysis. The
exposure variables were as follows: TNM stage (was codified as a
continuous variable), surgical treatment (treated vs. untreated),
smoking habit (never smokers vs. current smokers), and H. pylori
infection (positive vs. negative). Tests for interaction under a
multiplicative model showed no significant association of any
SNPs with tumor stage, surgery, smoking, and H. pylori status in
relation to survival (Tables S5 and S6). Only a weak significant
interaction between the PTGS2 rs4648298 AA genotype with
advance stages and reduced OS was observed (P interaction = 0.036).
Gene-gene interactions between all cytokine and PTGS poly-
morphisms were also investigated (Tables S7 and S8). Among all
interactions evaluated, the specific interaction between PTGS1
rs5788 and TGFB1 rs1800470 gene polymorphisms reached the
highest value. Thus, GAC patients carrying both mutant alleles
(rs5788A/rs1800470C) had a better OS than non-carriers (median
survival 595 days vs. 309; P-value = 0.007 by the log rank test;
Pinteraction = 0.002). However, after correction for multiple testing,
the association did not reach statistical significance (an interaction
term P-value,0.00001 was considered statistically significant after
correction for the number of interactions tested [23623 = 529;
0.05/529 = 9.5 1025].
In summary, of the environmental and clinicopathologic
features evaluated in this study and after controlling for
confounding factors, Cox regression analysis identified tumor
stages III (HR, 3.23; 95% CI: 2–5.22) and IV (HR, 5.5; 95% CI:
3.51–8.63) as independent factors associated with significantly
reduced OS, whereas surgical treatment (HR: 0.44;95%CI: 0.3–
0.6) was related to a better prognosis of the disease (Table 6).
Concerning genetic factors, none of the polymorphisms evaluated
in the current study were related to GAC prognosis. Moreover, no
interactions between any SNP’s and the identified prognostic
factors were observed.
Discussion
Since the publication in 2000 of the first landmark report by El-
Omar and co-workers [41] reporting the association of IL-1B
rs1143627T and IL1RN*2/*2 genotypes with an increased risk of
GAC, numerous studies concerning the association of cytokine
gene polymorphisms and GAC risk have been conducted.
However, few studies have addressed the role of cytokine gene
Table 3. Overall survival analysis according to cytokine gene
polymorphisms‘.
Gene SNP Genotype N HR* 95% CI P-value
IL1B rs16944 CC 178 – – –
CT 164 1.02 0.81–1.29 0.87
TT 38 1.03 0.70–1.53 0.88
Carrier T 202 1.02 0.82–1.28 0.85
IL1B rs1143634 CC 222 – – –
CT 139 0.98 0.77–1.24 0.86
TT 19 1.01 0.61–1.69 0.97
Carrier T 158 0.98 0.78–1.23 0.88
TNFA rs361525 GG 315 – – –
GA 64 0.78 0.57–1.05 0.1
AA 1 – – –
Carrier A 65 0.76 0.56–1.02 0.07
TNFA rs1800629 GG 290 – – –
GA 81 1.19 0.91–1.57 0.20
AA 9 0.40 0.15–1.06 0.07
Carrier A 90 1.07 0.82–1.40 0.61
LTA rs746868 CC 128 – – –
CG 180 0.94 0.73–1.21 0.64
GG 72 1.03 0.75–1.42 0.86
Carrier G 252 1.04 0.82–1.31 0.77
LTA rs909253 AA 222 – – –
AG 121 1.26 0.99–1.61 0.06
GG 37 1.02 0.68–1.52 0.93
Carrier G 158 0.83 0.67–1.05 0.12
IL12B rs3212227 AA 232 – – –
AC 126 1.01 0.80–1.29 0.91
CC 22 1.04 0.65–1.64 0.88
Carrier C 148 1.02 0.81–1.28 0.88
IL6 rs1800795 GG 157 – – –
GC 179 1.01 0.80–1.29 0.92
CC 44 1.19 0.82–1.73 0.35
Carrier C 223 1.04 0.83–1.31 0.71
IL10 rs2243250 CC 226 – – –
CA 133 0.78 0.62–0.99 0.04
AA 21 1.07 0.68–1.70 0.77
Carrier A 154 0.82 0.65–1.03 0.08
IL10 rs1800896 AA 112 – – –
GA 195 1.02 0.79–1.32 0.87
GG 73 1.27 0.92–1.76 0.15
Carrier G 268 1.08 0.85–1.38 0.53
TGFB1 rs1800470 TT 143 – – –
CT 161 0.94 0.73–1.21 0.62
CC 76 1.21 0.89–1.65 0.23
Carrier C 237 1.01 0.80–1.27 0.92
TGFB1 rs1800471 GG 327 – – –
GC 51 1.06 0.76–1.47 0.73
CC 2 0.98 0.24–3.96 0.98
Carrier C 53 0.97 0.76–1.46 0.74
Table 3. Cont.
Gene SNP Genotype N HR* 95% CI P-value
IL4 rs2243250 CC 263 – – –
CT 104 0.98 0.76–1.25 0.85
TT 13 0.95 0.52–1.74 0.86
Carrier T 117 0.97 0.77–1.24 0.82
IL1RN VNTR** Carrier
allele 2
169 – – –
Non carrier
allele 2
211 0.87 0.7–1.19 0.24
‘A comprehensive analysis was performed for all polymorphisms in the context
of different genetic models (dominant, recessive and codominant). Univariate
analyses done under codominant and dominant models are shown in the table.
*Unadjusted Hazard Ratio (HR) values.
**Variable number of tandem repeat polymorphism (VNTR) in intron 2 of the
IL1RN gene. N = number of individuals.
doi:10.1371/journal.pone.0046179.t003
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and other immune mediators on the prognosis of the disease. We
analyzed in this study a total of 23 polymorphisms localized in 11
immune-related genes (IL1B, TNFA, LTA, IL6, IL12p40, IL1RN,
IL4, IL10, TGFB1, PTGS1, and PTGS2). Concerning cytokine
genes, none of the polymorphisms analyzed in the current study
were related to GAC prognosis. This finding is in contrast with
those reported previously in two European studies conducted by
Graziano et al. [30] and Deans et al. [14]. The former [30] reported
the association of specific IL1B and IL1RN variants (IL1B
rs16944T/IL1B rs1143627C and IL1RN 1) with shortened survival
of patients with advanced GAC, and the later [14] showed the
association of the pro-inflammatory haplotype IL6 rs1800795C/
IL10 rs1800896G/TNFA rs1800629A with an adverse prognosis in
patients with squamous esophageal carcinoma or gastroesophageal
adenocarcinoma. However, the study by Graziano et al. [30] was
carried out in a series of 123 GAC patients with recurrent or
metastatic tumors treated with palliative chemotherapy, and the
study by Deans et al. [14] comprised a mixed population of
patients with GAC and patients with esophageal squamous cell
carcinoma. Our study was performed in a large non-selected
cohort of 380 Spanish Caucasian patients with primary GAC in
which patients with secondary or recurrent tumors and patients
with non-adenocarcinoma histology were excluded at entry. These
differences in design and methodology, along with geographical
variations in allele frequencies and the plausible effect of other
SNPs in these genes could explain, at least in part, the discrepant
results reported among studies.
With regard to cyclooxigenases, most studies have implicated
COX-2 as the COX isoform involved in cancer development and
invasiveness. By contrast, initial evidence for a role of COX-1 in
carcinogenesis was scarce. Recent studies reported a high
expression of COX-1 in malignant tissues of different types of
cancer such as ovarian, breast, and esophageal cancers [42–44]. In
addition, experimental studies in Min mice lacking the PTGS1 gene
showed a reduction in intestinal polyp formation compared to the
wild-type PTGS1+/Min mice [45]. Although the mechanisms by
which COX-1 is implicated in carcinogenesis are not well known,
it has been suggested that it is mediated through the induction of
COX-2 expression via a paracrine mechanism [46,47]. COX-1
and COX-2 proteins are encoded by the PTGS1 and PTGS2 genes
which are known to be highly polymorphic. In the last years,
several studies have addressed the role of PTGS1 and PTGS2
polymorphisms on GAC risk and its precursors with inconsistent
results [48–53]. However, and to our knowledge, this is the first
study evaluating the relevance of PTGS variants in the prognosis
and survival of GAC patients. In our study none of the PTGS1 and
PTGS2 polymorphisms were related to GAC prognosis. Only a
weak interaction between the rs4648298 polymorphism in the
PTGS2 gene with advance stages of the disease and reduced OS
was observed. Recently, two studies by Iglesias et al [54] and
Coghill et al [55] have reported the association of specific PTGS1
and PTGS2 gene variants with colorectal cancer survival. The
former described a link between the PTGS2 rs4648298G variant
and longer survival in a Spanish population of patients with
colorectal cancer. The latter, identified four PTGS1 polymor-
phisms influencing colorectal cancer mortality. According to the
authors, the rs12132666A variant was associated with 50% lower
mortality whereas minor alleles of the rs10306155, rs4836885, and
rs5789 resulted in significantly reduced patient’s survival. Howev-
er, and as point out by the authors, the magnitude of these
associations was attenuated after adjustment for stage of the
disease at diagnosis. In any case, these studies highlight the need
for further research to evaluate whether polymorphisms involved
in the prostaglandin synthesis pathway may have the potential to
predict survival in patients with GAC.
Similarly to what occurs to cytokine and PTGS genes, little
information is available with regard to genes encoding growth
factors. Among them, TGFB1 presents special interest due to its
role in gastric cancer development, progression and invasiveness
[23,24]. Two functional polymorphisms at positions +869 T.C
(rs1800470) and +915 G.C (rs1800471) in the signal protein
sequence of the TGFB1 gene [56,57] have been related to cancer
progression and patient’s survival in several types of cancer
[58,59]. In the current study, neither the rs1800470 nor the
Table 4. Overall survival analysis according to PTGS gene
polymorphisms‘.
Gene SNP Genotype N HR* 95% CI P-value
PTGS1 rs1330344 AA 233 – – –
AG 126 0.85 0.67–1.09 0.20
GG 21 1.15 0.63–1.83 0.55
Carrier G 147 0.89 0.71–1.12 0.39
PTGS1 rs3842787 CC 342 – – –
CT 36 0.97 0.66–1.41 0.86
TT 2 1.32 0.33–5.29 0.7
Carrier T 38 0.98 0.68–1.42 0.93
PTGS1 rs5788 CC 283 – – –
CA 88 0.79 0.60–1.03 0.09
AA 9 1.07 0.53–2.16 0.86
Carrier A 97 0.81 0.62–1.05 0.11
PTGS2 rs689466 AA 234 – – –
AG 136 0.99 0.79–1.25 0.96
GG 10 0.86 0.41–1.84 0.71
Carrier G 146 0.99 0.78–1.24 0.90
PTGS2 rs20417 GG 252 – – –
GC 116 0.93 0.73–1.19 0.55
CC 12 1.32 0.74–2.37 0.35
Carrier C 128 0.96 0.76–1.22 0.74
PTGS2 rs5277 GG 253 – – –
GC 116 1.02 0.80–1.30 0.87
CC 11 0.78 0.39–1.59 0.5
Carrier C 127 1 0.79–1.26 0.98
PTGS2 rs5275 TT 186 – – –
CT 157 0.94 0.74–1.19 0.62
CC 37 0.95 0.64–1.39 0.78
Carrier C 194 0.94 0.75–1.18 0.60
PTGS2 rs4648298 AA 359 – – –
AG 21 0.62 0.37–1.03 0.06
GG 0 – – –
Carrier G 21 0.62 0.37–1.03 0.06
PTGS2 rs689469 GG 360 – – –
GA 20 0.65 0.39–1.07 0.09
AA 0 – – –
Carrier A 20 0.65 0.39–1.07 0.09
‘A comprehensive analysis was performed for all polymorphisms in the context
of different genetic models (dominant, recessive and codominant). Univariate
analyses done under codominant and dominant models are shown in the table.
*Unadjusted Hazard Ratio (HR) values. N = number of individuals.
doi:10.1371/journal.pone.0046179.t004
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rs1800471 polymorphisms were associated with overall survival in
GAC patients. Moreover, no interaction with other clinicopath-
ological features such as H. pylori status, smoking habit, TNM stage
or surgical treatment was observed. In agreement with our results,
Guan et al [60] found no association between rs1800470 and
rs1800471 variants and OS rates, although in this case patients
carrying the rs1800471C variant showed a poorer 2-year survival
than non carriers.
Besides host factors, we also evaluate the relevance of
environmental factors, namely H. pylori infection and tobacco
smoking, as prognostic markers for GAC. We found that smoking
habit was independently associated with a worse prognosis,
especially in patients with earlier stages of the disease (HR: 1.78;
95% CI: 1.12–3.5). These findings are in agreement with one of
the few studies addressing this issue in which habitual smoking was
suggested as an adverse prognostic factor for gastric cancer in
Japanese patients [13]. Nicotine is considered the major psycho-
active compound of cigarette smoke and it has been well
documented to play a key role in gastric cancer [61,62]. However,
Table 5. Overall survival analysis according to cytokine and PTGS estimated haplotypes.
Genes Haplotypes N (%) *HR (95% CI) P-value
IL1RN/IL1B Non-carrier IL1RN*2/IL1B-511 C/IL1B+3954 C 151 (39.7) 0.91 (0.72–1.14) 0.42
Non-carrier IL1RN*2/IL1B-511 C/IL1B+3954 T 94 (24.7) 0.89 (0.69–1.15) 0.36
Non-carrier IL1RN*2/IL1B-511 T/IL1B+3954 C 86 (22.6) 0.95 (0.73–1.24) 0.69
Carrier IL1RN*2/IL1B-511 C/IL1B+3954 C 115 (30.3) 1.17 (0.92–1.48) 0.21
Carrier IL1RN*2/IL1B-511 C/IL1B+3954 T 57 (15.0) 1.07 (0.78–1.45) 0.68
Carrier IL1RN*2/IL1B-511 T/IL1B+3954 C 112 (29.5) 1.04 (0.82–1.33) 0.75
Carrier IL1RN*2/IL1B-511 T/IL1B+3954 T 4 (1.1) 1.25 (0.46–3.34) 0.66
TNFA/LTA TNFA -308 G/TNFA -238 G/LTA Nco I G/LTA Bsi C 88 (23.2) 1.14 (0.91–1.32) 0.62
TNFA -308 A/TNFA -238 G/LTA Nco I G/LTA Bsi C 91 (23.9) 1.09 (0.84–1.42) 0.52
TNFA -308 G/TNFA -238 G/LTA Nco I A/LTA Bsi C 154 (40.5) 1.05 (0.84–1.31) 0.67
TNFA -308 G/TNFA -238 A/LTA Nco I A/LTA Bsi C 65 (17.1) 0.76 (0.56–1.02) 0.07
TNFA -308 G/TNFA -238 G/LTA Nco I A/LTA Bsi G 252 (66.3) 0.97 (0.76–1.22) 0.76
TGFB1 TGFB1+869T/TGFB1+915G 304 (80.0) 0.80 (0.61–1.05) 0.11
TGFB1+869C/TGFB1+915G 203 (53.4) 1.01 (0.81–1.26) 0.94
TGFB1+869C/TGFB1+915C 53 (13.9) 1.06 (0.76–1.46) 0.74
IL10 IL -10 -597C/IL -10 -1087G 268 (70.5) 1.08 (0.85–1.38) 0.52
IL -10 -597C/IL -10 -1087A 201 (52.9) 0.94 (0.75–1.17) 0.56
IL -10 -597A/IL -10 -1087A 154 (40.5) 0.82 (0.65–1.07) 0.09
PTGS1 COX1 -1676A/COX1+50C/COX1+644C 351 (92.4) 0.96 (0.64–1.43) 0.82
COX1 -1676A/COX1+50C/COX1+644A 56 (14.7) 0.72 (0.52–1.05) 0.08
COX1 -1676G/COX1+50C/COX1+644C 77 (20.3) 0.91 (0.69–1.20) 0.51
COX1 -1676G/COX1+50C/COX1+644A 45 (11.8) 0.95 (0.68–1.33 0.76
COX1 -1676G/COX1+50T/COX1+644C 35(9.2) 0.91 (0.62–1.33) 0.62
PTGS2 COX2 -1195A/COX2 -765G/COX2+3050G/COX2+8473T/COX2+9850A/COX2+10335G 199 (52.4) 1.13 (0.90–1.41) 0.30
COX2 -1195A/COX2 -765G/COX2+3050G/COX2+8473C/COX2+9850A/COX2+10335G 85 (22.4) 0.90 (0.69–1.18) 0.44
COX2 -1195A/COX2 -765G/COX2+3050C/COX2+8473T/COX2+9850A/COX2+10335G 126 (33.2) 1 (0.79–1.27) 0.97
COX2 -1195A/COX2 -765C/COX2+3050G/COX2+8473C/COX2+9850A/COX2+10335G 107 (28.2) 1.09 (0.85–1.39) 0.51
COX2 -1195A/COX2 -765C/COX2+3050G/COX2+8473C/COX2+9850G/COX2+10335A 18 (4.7) 0.63 (0.37–1.08) 0.09
COX2 -1195G/COX2 -765G/COX2+3050G/COX2+8473T/COX2+9850A/COX2+10335G 145 (38.2) 0.92 (0.81–1.27) 0.91
COX2 -1195A/COX2 -765C/COX2+3050G/COX2+8473T/COX2+9850A/COX2+10335G 5 (1.3) 0.95 (0.35–2.55) 0.91
*Univariate analysis showing unadjusted Hazard Ratio (HR) values. Haplotypes with frequencies lower than 1% are not shown in the table.
N = number of individuals.
doi:10.1371/journal.pone.0046179.t005
Table 6. Multivariate Cox proportional hazard analysis for
GAC patients.
Variable N* HR 95% CI P-value
TNM Stage II 42 1.76 1.01–3.07 0.045
Stage III 64 3.23 2–5.23 ,0.001
Stage IV 176 5.50 3.51–8.62 ,0.001
Charlson Index $3 35 1.55 1.07–2.26 0.02
Surgical treatment 230 0.44 0.32–0.60 ,0.001
*N = number of individuals. The final number of GAC patients entered in the
model after excluding those individuals with missing values was 334 patients.
Covariables included in the model were the following: age, gender, Charlson
index, smoking habit, neoplasia site, TNM stage, surgical treatment, TNFA
rs361525, LTA rs909253, IL10 rs2243250, PTGS1 rs5788, and PTGS2 rs4648298
gene polymorphisms.
doi:10.1371/journal.pone.0046179.t006
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its effect on angiogenesis and invasion remains largely unknown,
although recent experimental studies have showed that nicotine
can stimulate gastric cancer cell proliferation, migration and
invasiveness through a COX-2/VEGF dependent pathway [63].
Regarding the influence of H. pylori status in GAC outcome, we
found no association between bacterial infection and GAC
prognosis. Recent studies have suggested that H. pylori infection
may be related to better prognosis in patients with GAC.
Meimarakis et al. [64] demonstrated that infection prior to
curative-intent resection of GAC correlated with both higher
relapse-free and OS rates in early stages cancers (T1 and T2). H.
pylori status was also found to influence survival in patients with
early as well as advanced stages of disease in a subsequent study by
Marrelli et al. [10]. The reasons for this association are not known
but it was explain on the basis of an improved immune response
against the tumor induced by H. pylori [64]. However, this
hypothesis was not confirmed by other studies [65,66], including
our own, suggesting that H. pylori negativity may be simply related
with more advanced stages or progression of the disease.
Finally, our study has several strengths and limitations. This
investigation was carried out in a homogeneous Caucasian
population of Spanish patients with primary GAC followed for a
long period of time. Moreover, and to our knowledge, this is the
first study evaluating the relevance of PTGS1 and PTGS2 variants
in the prognosis and survival of GAC patients. On the other hand,
some limitations should be also considered. In particular, the
relatively small sample size limited the power to detect smalls HRs
in those low-frequency homozigous variant polymorphisms.
Setting an a value of 0.05, the study had a power of 85% to
detect HRs .1.4. As a result, it is possible that we could miss
minor statistical differences especially when subgroup analyses and
assessment of gene-environmental interactions were performed. A
second limitation of the study was the lack of a centralized
pathological assessment. Evaluation of biopsies and surgical
specimens was accomplished at each participant hospital which
may represent a source of bias since interobserver variability was
not controlled. Variables affecting GAC survival in our study
(TNM stage and surgical treatment) have been described as
common prognostic factors in the Literature [14,60,67]. In the
survival analysis, only surgical treatment information was consid-
ered for evaluation although data regarding chemo- and
radiotherapy were also available. However, radiotherapy and
chemotherapy schedules varied considerably among the partici-
pating hospitals which precluded a reliable assessment of their
effects on disease outcome. Further studies evaluating potencial
interactions between clinical and gene polymorphisms on GAC
survival should take into consideration the relevance of including a
detailed treatment information which could help to identify
interactions that may have direct implications for therapy and
follow-up strategies.
In summary, our data show that the specific polymorphisms
among pro- and anti-inflammatory cytokine and PTGS gene
polymorphisms evaluated in this study are not related to GAC
prognosis in the Spanish population. However, we can not rule out
that further studies with larger sample size could detect as
statistically significant some small differences found in our study.
Future genome-wide association studies (GWAS) and well
designed studies in different areas and ethnic groups are needed
in order to determine the real contribution of host genetic factors
into the prognosis of gastric cancer.
Supporting Information
Figure S1 Kaplan-Meier survival plots in cardia GAC
patients. Kaplan-Meier survival plots in cardia GAC patients
(n = 63) presented by (A) TNM stage, (B) surgical treatment, (C)
age, (D) gender, (E) smoking habit, (F) and H. pylori infection status
(G). Statistical analysis was performed by the log-rank test.
(TIF)
Figure S2 Kaplan-Meier survival plots in non-cardia
GAC patients. Kaplan-Meier survival plots in non-cardia GAC
patients (n = 317) presented by (A) TNM stage, (B) surgical
treatment, (C) age, (D) gender, (E) smoking habit, (F) and H. pylori
infection status. Statistical analysis was performed by the log-rank
test.
(TIF)
Figure S3 Kaplan-Meier survival plots in intestinal GAC
patients. Kaplan-Meier survival plots in intestinal GAC patients
(n = 161) presented by (A) TNM stage, (B) surgical treatment, (C)
age, (D) gender, (E) smoking habit, (F) and H. pylori infection status.
Statistical analysis was performed by the log-rank test.
(TIF)
Figure S4 Kaplan-Meier survival plots in diffuse GAC
patients. Kaplan-Meier survival plots in diffuse GAC patients
(n = 119) presented by (A) TNM stage, (B) surgical treatment, (C)
age, (D) gender, (E) smoking habit, (F) and H. pylori infection status.
Statistical analysis was performed by the log-rank test.
(TIF)
Table S1 Demographic and clinicopathological charac-
teristics of GAG patients stratified according to the
location of the tumor (cardia/non-cardia) and histolog-
ical subtype (intestinal/diffuse).
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Table S2 Overall survival analysis and clinicopatholog-
ical features in GAC patients stratified according to the
location of the tumor (cardia/non-cardia).
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Table S3 Overall survival analysis and clinicopatholog-
ical features in GAC patients stratified according to the
histological type of the tumor (intestinal/diffuse).
(DOC)
Table S4 Overall survival analysis and gene polymor-
phisms according to the location and histological
subtype of the tumor.
(DOC)
Table S5 Interaction between cytokine gene polymor-
phisms and clinicopathological features.
(DOC)
Table S6 Interaction between PTGS gene polymor-
phisms and clinicopathological features.
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Table S7 Gene-gene interactions between cytokine and
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Table S8 Gene-gene interactions between cytokine and
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